Quality Management & Compliance Services

Cisema’s quality management and compliance services help companies in the Life Sciences, health foods, consumer and industrial goods industries achieve and maintain regulatory compliance cross the Asia-Pacific region including China.

Our expert teams design, adapt, and implement quality management systems aligned with Chinese and international quality standards, ensuring product safety, regulatory approval, and ongoing quality compliance. We support every stage of the product lifecycle, from initial market entry to post-market surveillance, enabling you to meet the strictest quality management standards and quality expectations while delivering quality products that meet customer expectations.

Vietnam medical device registration
Quality compliance

Industry-Specific Quality Management Expertise

Pharmaceuticals & Biotech

We provide comprehensive pharmaceutical quality management compliance consulting to help companies meet Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and Good Pharmacovigilance Practice (GVP) standards. Our quality assurance and quality control services include:

  • Quality system and SOP development aligned with NMPA and Asia-Pacific regulatory requirements
  • GxP audits, gap analysis, and inspection readiness
  • Vendor qualification and supply chain oversight to ensure manufacturing processes meet industry standards
  • Ingredient compliance verification and regulatory documentation checks
  • Pre-approval inspection support, corrective action planning, and continuous improvement initiatives
Read More
Close

Medical Devices & In-Vitro Diagnostics (IVDs)

We provide quality management and compliance services for medical devices and IVDs in China, Hong Kong, Taiwan, and the six ASEAN countries we cover: Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines. Each market has unique regulatory requirements, and our team ensures your quality management system meets both local rules and international quality standards.

In China, the NMPA demands compliance beyond ISO 13485, incorporating Chinese GMP. Hong Kong follows MDACS, with a focus on classification, safety, and quality control. Taiwan’s TFDA requires harmonisation with ISO 13485 plus local compliance requirements. Across ASEAN, each regulator, from Singapore’s HSA to the Philippines’ FDA, has distinct industry standards and inspection protocols.

We help you navigate them all with:

  • Gap analysis and adaptation for multi-market compliance
  • SOP, work instruction, and record optimisation
  • Supplier qualification, audit programs, and CAPA planning to improve quality
  • Inspection preparation and on-site support to avoid non-compliance
  • Post-market surveillance, vigilance, and reporting tailored to each jurisdiction

Our approach unifies your global quality processes while tailoring to each market, so you meet quality expectations, safeguard market access, and deliver quality products customers trust.

Read More
Close

Cosmetics & Cosmetic Ingredients

We deliver quality management and compliance services for cosmetics and ingredients in China and Taiwan, two highly regulated markets where strong quality management standards and precise compliance requirements are non-negotiable.

In China, the CSAR framework requires a quality management system aligned with NMPA Cosmetic GMP that goes beyond ISO 22716. That means strict quality control, traceability, and adherence to regulatory requirements for every product. We prepare you with mock audits, SOP localisation into Chinese, CAPA programs, and lifecycle monitoring to eliminate non compliance and protect your market position.

In Taiwan, TFDA regulations align with ISO 22716, the internationally recognised cosmetics GMP standard, which sets best practices for production, quality control, storage, and shipment. We implement quality systems that fully comply with ISO 22716 and local TFDA rules, ensuring product safety and robust quality assurance throughout your manufacturing processes.

Our services include:

  • Gap analysis for NMPA and TFDA compliance
  • SOP development, localisation, and integration into company's processes
  • Supplier qualification and oversight to meet industry standards
  • Pre-audit and inspection readiness with bilingual support
  • CAPA follow-up for continual improvement
Read More
Close

Health Foods, Dietary Supplements & Foods for Special Medical Purposes

China's State Administration for Market Regulation (SAMR) enforces stringent quality control for supplements, functional foods, and FSMP. We support compliance by:

  • Establishing or enhancing a quality management system for special foods in line with Chinese GMP to produce quality products
  • Conducting gap assessments and documentation localisation
  • Preparing for self-inspections and regulatory site visits
  • Implementing product traceability, contamination prevention, and CAPA systems
  • Ensuring regulatory alignment for labelling, claims, and shelf-life validation
Read More
Close

Veterinary Medicines & Products

Veterinary products face rigorous regulatory obligations for safety, efficacy, and quality in China. We assist with:

  • QMS design and documentation control to meet company's operations objectives
  • GMP audits and inspection readiness to prevent reputational damage
  • Supplier oversight and raw material compliance verification with external partners
  • Lifecycle quality monitoring and continual improvement programs
Read More
Close

Industrial Goods & Consumer Products

For industrial and consumer goods, especially where a China Manufacturer License (CML) or SELO compliance is required, we offer:

  • Consultation workshops and regulatory briefings creating awareness of compliance requirements
  • On-site and remote friendly audits with gap analysis and action plans
  • QMS handbook review and adaptation to SELO management and control measures
  • Documentation readiness checks for factory inspections to ensure compliance with all regulations.
Read More
Close

Why Work with Cisema?

One Partner, Full Lifecycle Support

From pre-market strategy to post-market compliance, we provide support to internal regulatory teams and ensure seamless lifecycle management.

Regional Reach, Global Presence

Based in Asia and Europe with a global team delivering global reach.

Cross-Industry Expertise

Pharma, biotech, medical devices, cosmetics, supplements, veterinary, industrial and consumer goods.

Proven Results

Over 20 years of regulatory submissions, regulatory expertise, and approvals to drive business success.

Market Access Consulting

Latest Insights

View More

China Issues Six Technical Guidelines (Trial) for Hair Dye, Perming, & Sunscreen Cosmetics 

China’s NIFDC releases 6 new technical guidelines for high-risk cosmetics, impacting hair dye, perming, and sunscreen product compliance.

May 8, 2026
China Issues Six Technical Guidelines (Trial) for Hair Dye, Perming, & Sunscreen Cosmetics 
A young Asian woman in understated casual clothing holding a single unbranded boxed hair dye product slightly angled toward her as she studies the ingredient panel.

Hong Kong Launches Primary Evaluation Phase 1 for NDAs

Hong Kong introduces Primary Evaluation Phase 1 for NDAs, requiring pathway selection across 3 routes and reshaping drug registration strategy.

May 6, 2026
Hong Kong Launches Primary Evaluation Phase 1 for NDAs
A single Asian scientist in their 30s wearing a lab coat, safety glasses, and nitrile gloves seated at a tidy bench in a modern pharmaceutical laboratory in Hong Kong, calmly reviewing a few printed documents while referencing a simple laptop screen

Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138

Hong Kong confirms injectable products are generally classified as pharmaceutical products under Cap. 138, impacting medical aesthetics and borderline products

May 8, 2026
Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138
Minimalist, well-lit medical aesthetics clinic in Hong Kong. An Asian female doctor in a simple white coat and disposable gloves sits beside a female patient, holding a single unbranded prefilled syringe at chest level.

China April 2026 Reforms Reshape Drug Approval, Pricing, & Access

The reforms introduce new drug pricing rules, clarified conditional approval procedures, and tiered care measures.

May 8, 2026
China April 2026 Reforms Reshape Drug Approval, Pricing, & Access
Chinese scientists gathered around a bottle of medicine

Taiwan Abolishes Legacy Cosmetics Review Fees

TFDA eliminates legacy cosmetics review fees, reducing compliance costs for foreign companies.

May 5, 2026
Taiwan Abolishes Legacy Cosmetics Review Fees
Team reviews cosmetics documents for regulatory compliance and market access in Taiwan

CMDE Unveils 2026–2027 Roadmap for Medical Device Registration Guidelines, Emphasizing AI, IVDs, and High-Risk Technologies

CMDE maps 275 guideline updates, tightening requirements and giving manufacturers early visibility for planning and compliance.

May 5, 2026
CMDE Unveils 2026–2027 Roadmap for Medical Device Registration Guidelines, Emphasizing AI, IVDs, and High-Risk Technologies
dermatology treatment room in a modern Chinese hospital, medium shot: a licensed clinician in medical scrubs and protective eyewear performing a laser skin procedure using a professional Nd:YAG laser system
Previous
Previous

Get in Touch with Our Quality Management & Compliance Consultants

Contact our quality management and compliance services team today to discover how we can strengthen your systems, secure your market access, and maintain compliance across every stage of your product lifecycle.

Request Proposal